Singular Genomics Systems Past Earnings Performance
Past criteria checks 0/6
Singular Genomics Systems's earnings have been declining at an average annual rate of -25.3%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 129.4% per year.
Key information
-25.3%
Earnings growth rate
26.6%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 129.4% |
| Return on equity | -53.0% |
| Net Margin | -3,257.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Singular Genomics Systems makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3 | -95 | 53 | 48 |
| 30 Sep 23 | 3 | -93 | 51 | 47 |
| 30 Jun 23 | 2 | -94 | 50 | 48 |
| 31 Mar 23 | 2 | -93 | 49 | 48 |
| 31 Dec 22 | 1 | -91 | 47 | 46 |
| 30 Sep 22 | 0 | -90 | 46 | 45 |
| 30 Jun 22 | 0 | -83 | 42 | 41 |
| 31 Mar 22 | 0 | -97 | 36 | 37 |
| 31 Dec 21 | 0 | -99 | 29 | 33 |
| 30 Sep 21 | 0 | -87 | 20 | 29 |
| 30 Jun 21 | 0 | -77 | 13 | 26 |
| 31 Mar 21 | 0 | -47 | 9 | 24 |
| 31 Dec 20 | 0 | -28 | 6 | 21 |
Quality Earnings: OMIC is currently unprofitable.
Growing Profit Margin: OMIC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OMIC is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.
Accelerating Growth: Unable to compare OMIC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OMIC is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-9.3%).
Return on Equity
High ROE: OMIC has a negative Return on Equity (-52.97%), as it is currently unprofitable.